

Oncology/Haematology Portfolio (approved products & pipeline)



LABORATOIRES

Pierre Fabre

New ways to care

Oncology/Haematology Portfolio

INN / Compound	Class	Indication or disease	Discovery	Preclinical	Phase I	Phase II	Phase III	In Registration	Approved *	
Vinorelbine	Chemo-therapy	Advanced BREAST CANCER as monotherapy or in combination with other agents	▶							■
		Advanced NSCLC as monotherapy or in combination with other chemotherapies	▶							■
		Adjuvant treatment of NSCLC in combination with platinum-based chemotherapy	▶							■
Vinflunine	Chemo-therapy	Advanced or metastatic transitional-cell carcinoma of the UROTHELIAL tract	▶							■
Neratinib ¹	Targeted therapy	HER2 amplified / overexpressed / HR + early BREAST CANCER (extended adjuvant post trastuzumab based therapy)	▶							■
Tabelec-Leuce ²	T-cell immunotherapy	Epstein-Barr virus associated post-transplant lymphoproliferative disease (EBV+ PTLD)	▶							■

* Approved at least by EMA. Vinorelbine was approved by National Health Authorities (before EU centralized procedure implementation)

1. Commercialized in partnership with Puma Biotechnology
2. Commercialized in partnership with Atara Biotherapeutics

Products should be used in accordance with their approved prescribing information. Information about the trials can be found at www.ClinicalTrials.gov

Oncology Portfolio

INN / Compound	Class	Target and Modality	Indication or disease	Discovery	Preclinical	Phase I	Phase II	Phase III
Exarafenib ¹	Targeted therapy	Pan-RAF small molecule Inhibitor	NRAS mutant MELANOMA and other BRAF / NRAS mutant solid tumors					
PFL-721 / STX-721 ²	Targeted therapy	Mutant-selective EGFR-exon20 small molecule inhibitor	NSCLC with EGFR exon 20 insertion mutation					
PFL-241 / STX-241 ²	Targeted therapy	Mutant-selective 4th generation EGFR small molecule inhibitor	NSCLC with EGFR exon 19/21 + C797S mutations					
PFL-002 / VERT-002 ³	Targeted therapy	Anti-cMET antibody degrader	NSCLC / solid tumors with mutations or amplification of MET					
Not-disclosed ⁴	Targeted therapy	Multiple targets	ONCOLOGY					

1. Originated by Kinnate Biopharma Inc. Investigational Pan-RAF Inhibitor, Exarafenib, acquired by Pierre Fabre Laboratories

2. Co-development in partnership with Scorpion Therapeutics Inc., Boston, USA. The sponsor of these studies could be Pierre Fabre Medical Care or Scorpion Therapeutics Inc.

3. Originated by Vertical Bio AG, acquired by Pierre Fabre Laboratories

4. Discovery partnership with Vernalis Ltd.

This display includes ongoing clinical trials for both approved and investigational compounds. Inclusion in this display does not imply regulatory approval for these compounds or all indications. Products should be used in accordance with their prescribing information. Information about the trials can be found at www.ClinicalTrials.gov